Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PFE by emailGet an email when PFE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PFE, unsubscribe in one click. Privacy
📣 What PFE Says Is Next
in 2026 · “These data support Pfizer’s plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials.”
Company press release, Aug 4, 2026 · SEC filing
this year · “Phase 3 planning for atopic dermatitis is ongoing, with a pivotal study on track to start this year.”
Company press release, May 5, 2026 · SEC filing
in 2026 · “Robust Late‑Stage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026 NEW YORK, Tuesday, May 5, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance (2) .”
Company press release, May 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PFE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PFE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.